Free Trial

ResMed (RMD) Stock Price, News & Analysis

-0.95 (-0.43%)
(As of 03:27 PM ET)
Today's Range
50-Day Range
52-Week Range
196,483 shs
Average Volume
1.03 million shs
Market Capitalization
$32.00 billion
P/E Ratio
Dividend Yield
Price Target

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
6.9% Downside
$202.80 Price Target
Short Interest
6.70% of Shares Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.95mentions of ResMed in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$5.40 M Sold Last Quarter
Proj. Earnings Growth
From $7.64 to $8.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Medical Sector

77th out of 921 stocks

Surgical & Medical Instruments Industry

13th out of 100 stocks

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

ResMed Inc. (NYSE:RMD) Director Sells $78,584.40 in Stock
(RMD) - Analyzing ResMed's Short Interest
ResMed Inc. (RMD) Q3 2024 Earnings Call Transcript
Why ResMed Stock Is Soaring Today
Australian Stocks: ResMed (RMD) Shares Surge on Robust Q3 Results
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/14 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 6/13 Dividend
Dividend Payable
Fiscal Year End
Next Earnings (Estimated)

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$897.56 million
Pretax Margin


Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.74 per share
Book Value
$28.11 per share


Free Float
Market Cap
$31.85 billion

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

RMD Stock Analysis - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price target for 2024?

10 Wall Street research analysts have issued 12 month target prices for ResMed's shares. Their RMD share price targets range from $165.00 to $238.00. On average, they predict the company's share price to reach $202.80 in the next year. This suggests that the stock has a possible downside of 6.9%.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2024?

ResMed's stock was trading at $172.02 on January 1st, 2024. Since then, RMD stock has increased by 26.6% and is now trading at $217.79.
View the best growth stocks for 2024 here

Are investors shorting ResMed?

ResMed saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 9,850,000 shares, an increase of 23.9% from the April 15th total of 7,950,000 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is currently 9.0 days.
View ResMed's Short Interest

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our RMD earnings forecast

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, April, 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.22. The medical equipment provider had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.17 billion. ResMed had a trailing twelve-month return on equity of 24.43% and a net margin of 20.91%. ResMed's revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.68 EPS.
Read the conference call transcript

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, April 25th. Shareholders of record on Thursday, May 9th will be given a dividend of $0.48 per share on Thursday, June 13th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Wednesday, May 8th.
Read our dividend analysis for RMD

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 0.88%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 29.49%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 22.27% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (12.10%), Bank of New York Mellon Corp (2.59%), Congress Asset Management Co. MA (0.40%), Los Angeles Capital Management LLC (0.34%), Tandem Investment Advisors Inc. (0.33%) and Swiss National Bank (0.30%). Insiders that own company stock include Brett Sandercock, Carol Burt, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Witte Jan De.
View institutional ownership trends

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
This page (NYSE:RMD) was last updated on 5/21/2024 by Staff

From Our Partners